Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 271 results
Filters: Keyword is HIV-1  [Clear All Filters]
Found 271 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

A

Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Valcour V, Yeh T-M, Bartt R, et al. "Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection." HIV Med.. 2009;10(2):103-10.
Pond SLKosakovs, Frost SDW, Grossman Z, Gravenor MB, Richman DD, Brown AJLeigh. "Adaptation to different human populations by HIV-1 revealed by codon-based analyses." PLoS Comput. Biol.. 2006;2(6):e62.
John M, Heckerman D, James I, et al. "Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs." J. Immunol.. 2010;184(8):4368-77.
Amorosa VK, Luetkemeyer A, Kang M, et al. "Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial." HIV Clin Trials. 2013;14(6):274-83.
Schooley RT, Spritzler J, Wang H, et al. "AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein." J. Infect. Dis.. 2010;202(5):705-16.
Smurzynski M, Collier AC, Koletar SL, et al. "AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics." HIV Clin Trials. 2008;9(4):269-82.
McCausland MR, Juchnowski SM, Zidar DA, et al. "Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy." PLoS ONE. 2015;10(10):e0139474.
Gripshover BM, Ribaudo H, Santana J, et al. "Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)." Antivir. Ther. (Lond.). 2006;11(5):619-23.
Eshleman SH, Hudelson SE, Redd AD, et al. "Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial." J. Infect. Dis.. 2011;204(12):1918-26.
Taiwo B, Gallien S, Aga E, et al. "Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy." J. Infect. Dis.. 2011;204(4):515-20.
Lockman S, Hughes MD, McIntyre J, et al. "Antiretroviral therapies in women after single-dose nevirapine exposure." N. Engl. J. Med.. 2010;363(16):1499-509.
Zheng Y, Hughes MD, Lockman S, et al. "Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens." Clin. Infect. Dis.. 2014;59(6):888-96.
George E, Noël F, Bois G, et al. "Antiretroviral therapy for HIV-1-infected children in Haiti." J. Infect. Dis.. 2007;195(10):1411-8.
Volberding P, Demeter L, Bosch RJ, et al. "Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment." AIDS. 2009;23(15):1987-95.
Richman DD. "Antiviral drug resistance." Antiviral Res.. 2006;71(2-3):117-21.
Hosoya N, Su Z, Wilkin T, et al. "Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions." J. Clin. Microbiol.. 2009;47(8):2604-6.
Mollan KR, Smurzynski M, Eron JJ, et al. "Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data." Ann. Intern. Med.. 2014;161(1):1-10.
Cu-Uvin S, Snyder B, Harwell JI, et al. "Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months." J. Acquir. Immune Defic. Syndr.. 2006;42(5):584-7.
Demeter LM, Degruttola V, Lustgarten S, et al. "Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience." HIV Clin Trials. 2008;9(1):11-25.
McLinden RJ, Paris RM, Polonis VR, et al. "Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)." AIDS. 2012;26(1):1-9.
Kang M, Cu-Uvin S. "Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy." HIV Med.. 2012;13(6):372-8.
McLaren PJ, Coulonges C, Ripke S, et al. "Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls." PLoS Pathog.. 2013;9(7):e1003515.
Foulkes AS, Wohl DA, Frank I, et al. "Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy." PLoS Med.. 2006;3(3):e52.
Daar ES, Tierney C, Fischl MA, et al. "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1." Ann. Intern. Med.. 2011;154(7):445-56.

Pages